<DOC>
	<DOC>NCT00877149</DOC>
	<brief_summary>The purpose of this trial is to provide data of absence of inflammation in patient liver histology after long-term telbivudine treatment and thus help investigators to make a comprehensive judgment on treatment discontinuation in selected patients</brief_summary>
	<brief_title>Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Patient completed study CLDT600ACN04 study and will be available to immediately rollover into this study without discontinuation of study drug. Patient was not discontinued from the previous CLDT600ACN04 study. Adult patients with CHB (HBeAg positive or HBeAg negative). HBV DNA PCR undetectable in recent 12 months. Pregnant or breastfeeding, or has plan of pregnant during study period. Patient is coinfected with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV at screening visit. Patient has received within the past 12 months any antiHBV treatment combination (addon therapy) or switch to other anti HBV treatment from Telbivudine at investigator's discretion. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Chronic HBV</keyword>
</DOC>